Table 1.
Characteristics of the 12 Ovarian Cancer Case-Control Studies from the Ovarian Cancer Association Consortium, Conducted in Australia, Europe, and North America Between 1989 and 2010
| Response Rate % | Controls, n(%) | All cancer, n(%) | Mucinous, n(%) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | Region | Study Name | Study Period | Study Type | Method of Data Collection | Matching Variables | Cases | Controls | Total number of parous women2 | Age (years), mean (SD) | Never gave birth to a boy | Ever gave birth to a boy | Never gave birth to a boy | Ever gave birth to a boy | Adjusted OR (95% CI) model3 | Never gave birth to a boy | Ever gave birth to a boy | Adjusted OR (95% CI) model3 |
| AUS | Australia | Australian Ovarian Cancer Study | 2002–2005 | Population-based | Self-administered questionnaire | Age (5-year categories) Age (3 age groups: | 84 | 47 | 2337 | 57.9 (11.1) | 233 (19.3) | 972 (80.7) | 218 (19.3) | 914 (80.7) | 1.11 (0.89, 1.40) | 16 (12.9) | 108 (87.1) | 1.90 (1.07, 3.39) |
| CON | USA | Connecticut Ovarian Cancer Study | 1998–2003 | Population-based | In-person interview | 35–49 years, 50–64 years, and 65–79 years) | 69 | 61 | 826 | 55.70 (10.96) | 105 (23.2) | 348 (76.8) | 90 (24.1) | 283 (75.9) | 1.09 (0.76, 1.56) | 6 (16.2) | 31 (83.8) | 1.70 (0.66, 4.41) |
| GER | Germany | Germany Ovarian Cancer Study | 1993–1996 | Population-based | Self-administered questionnaire | Age and study region | 58 | 51 | 642 | 56.3 (10.6) | 125 (29.0) | 306 (71.0) | 75 (35.6) | 136 (64.5) | 0.70 (0.47, 1.05) | 9 (33.3) | 18 (66.7) | 0.77 (0.30, 1.99) |
| HAW | USA | Hawaii Ovarian Cancer Case- Control Study | 1993–2008 | Population-based | In-person interview | Age (5-year categories, race/ethnicity) | 78 | 80 | 1507 | 56.5 (13.9) | 181 (20.2) | 715 (79.8) | 128 (21.0) | 483 (79.0) | 1.06 (0.80, 1.41) | 25 (22.5) | 86 (77.5) | 1.14 (0.67, 1.94) |
| HOP | USA | Hormones and Ovarian Cancer Prediction Study | 2003–2008 | Population-based | In-person interview | Age (5-year categories), Race, Telephone prefix | 71 | 68 | 2176 | 59.4 (12.4) | 315 (20.7) | 1207 (79.3) | 146 (22.3) | 508 (77.7) | 0.94 (0.73, 1.20) | 10 (25.0) | 30 (75.0) | 0.97 (0.43, 2.17) |
| NCO | USA | North Carolina Ovarian Cancer Study | 1999–2008 | Population-based | In-person interview | Age (5-year categories, race/ethnicity) | 67 | 60 | 1819 | 56.5 (11.0) | 207 (22.8) | 700 (77.2) | 206 (22.6) | 706 (77.4) | 1.07. (0.84, 1.37) | 14 (17.1) | 68 (82.9) | 2.27 (1.16, 4.45) |
| NJO | USA | New Jersey Ovarian Cancer Study | 2002–2008 | Population-based | In-person interview | No matching Age (3 age groups: | 47 | 40 | 524 | 62.4 (11.1) | 92 (25.1) | 275 (74.9) | 41 (26.1) | 116 (73.9) | 1.12 (0.69, 1.82) | 2 (40.0) | 3. (60.0) | - |
| SON | Canada | Southern Ontario Ovarian Cancer Study | 1989–1993 | Population-based | In-person interview | 35–49 years, 50–64 years, and 65–79 years) | 71 | 65 | 792 | 56.7 (11.7) | 88 (18.8) | 379 (81.2) | 82 (25.2) | 243 (74.8) | 0.76 (0.53, 1.10) | 12 (20.0) | 48 (80.0) | 0.81 (0.40, 1.67) |
| TBO | USA | Tampa Bay Ovarian Cancer Study | 2000-present | Population-based | In-person interview | Age (5-year categories, race) | 68 | 60 | 163 | 61.3 (10.2) | 23 (31.1) | 51 (68.9) | 18 (20.2) | 71 (79.8) | 1.53 (0.60, 3.89) | 0 (0.0) | 1 (100.0) | - |
| TOR | Canada | Familial Ovarian Tumour Study (FOTS) AND Health Watch (HW) | FOTS: 1995-1999 and 2000-2003; HW: 1995-2000 | Population-based | In-person interview | Age (5-year categories) | 50 | 80 | 1135 | 57.3 (12.2) | 48 (17.1) | 233 (82.9) | 164 (19.2) | 690 (80.8) | 1.04 (0.71, 1.52) | 23 (18.3) | 103 (81.7) | 1.34 (0.73, 2.46) |
| UKO | UK | United Kingdom Ovarian cancer Population Study | 2006–2010 | Hospital- based | In-person interview | No matching | 86 | 97 | 1268 | 63.5 (8.0) | 180 (21.7) | 648 (78.3) | 98 (22.3) | 342 (77.7) | 1.05 (0.76, 1.45) | 11 (28.2) | 28 (71.8) | 1.17 (0.51, 2.69) |
| USC | USA | Los Angeles County Case- Control Studies of Ovarian Cancer | 1993–2009 | Population-based | In-person interview | Age (5-year categories, race/ethnicity) | 73 | 73 | 2784 | 56.9 (11.2) | 362 (21.7) | 1308 (78.3) | 212 (19.0) | 902 (81.0) | 1.17 (0.95, 1.44) | 19 (23.2) | 63 (76.8) | 0.92 (0.52, 1.64) |
| Pooled | - | - | - | 15973 | 58.0 (11.6) | 1959 (21.5) | 7142 (78.5) | 1478 (21.5) | 5394 (78.5) | 1.04 (0.95, 1.13) | 147 (20.0) | 587 (80.0) | 1.25 (1.00, 1.56) | |||||
1
Although TOR controls were limited to relatives and in-laws, it should not affect the exposure of interest, offspring sex Thus, cases and controls from TOR can all be included in the currect analysis
2
Excludes women with non-singleton births (n=528), missing core data (n=35), and missing offspring sex data (n=335)
3
Adjusted for age at diagnosis/reference date (continous), race (Black, White, Asian, Other), duration of oral contraceptive use (never, less than 1 years, 1–4 years, 5–9 years, and more than 10 years) and number of full-term pregnancies (1, 2, 3, 4, 5+)